Newslish
πŸ“°Read
🎧Listen
βœ…Quiz
πŸ”–Save words
LiveLesson #78Health

Ebola Vaccine Development in Progress

Scientists are racing to develop vaccines and treatments for the Bundibugyo strain of Ebola in the DRC and Uganda, with emergency funding awarded to accelerate efforts.

Pick your level

Standard β€” Natural English

Standard version (B1–B2)

The Bundibugyo strain of Ebola is spreading in the Democratic Republic of the Congo (DRC) and Uganda, and currently, there is no vaccine or treatment available. Recently, three vaccine developers received $60 million in emergency funding to expedite the development of solutions. However, security issues in the DRC complicate the setup of clinical trials. Researchers are eager to begin testing as soon as conditions improve, emphasizing the urgency of the situation.

Lesson audio

Standard level

Tap to play

0:28

Quick quiz

01What strain of Ebola is currently spreading in the DRC and Uganda?

02How much emergency funding was awarded to vaccine developers?

03What organization announced the funding for vaccine development?

04What is the expected timeline for clinical trials of the rVSV Bundibugyo vaccine?

Key vocabulary

  • vaccine word

    a substance used to stimulate the production of antibodies and provide immunity against diseases.

    β€œThe new vaccine aims to protect against the Bundibugyo strain of Ebola.”

  • treatment word

    the management and care of a patient for the purpose of combating a disease.

    β€œResearchers are working on new treatments for Ebola.”

  • funding word

    money provided for a specific purpose.

    β€œThe vaccine developers received $60 million in emergency funding.”

  • clinical trials word

    research studies that test how well new medical approaches work in people.

    β€œThe WHO expects clinical trials to begin within months.”

  • urgency word

    importance requiring swift action.

    β€œThere is a sense of urgency in combating the Ebola outbreak.”

Discussion prompt

What challenges do you think researchers face when developing vaccines in conflict zones?